Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training.

Slides:

Advertisements

Similar presentations

Gilead’s Tech Transfer Partnerships and IP in India

Advertisements

 Definition  The demand continues  Is an academic career a good fit for you ?  Academia: many roles outside classroom  Role of faculty member ◦ Teaching.

WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

A Community Health Center’s Perspective on the Feasibility, Reality and Benefits of Research Myechia Minter-Jordan MD, MBA President and CEO The Dimock.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Special Topics in IND Regulation

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.

Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.

Use of Antivirals in Prevention Oral and Topical Prophylaxis

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

AIDS By Brandon p. Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the.

Building Trusted Partnerships for HIV Prevention: Danger and Opportunity for Public Health & the Church The Effects of the AIDS Pandemic and Poverty on.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.

HIV/AIDS VACCINE AWARENESS Vaccine 101 Jeremiah Brewer Health and Training Educator African – Americans Reach and Teach Health Ministry.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.

Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,

Food and Drug Administration

Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.

Topical Microbicides Antiviral Drugs Advisory Committee August 20, 2003.

Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,

WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.

HOW ARE MDP PREPARING COMMUNITIES AT TRIAL SITES? MDP301.

Welcome South Africa 4 Rectal Microbicides A Stakeholder Consultation on Rectal Microbicide Research and Advocacy Please sign in.

Applicability of Existing Regulations to the Development of a Dendrimer Nanotechnology-Based Pharmaceutical Presentation to Advisory Committee for Pharmaceutical.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

HIV-1 Resistance Testing in Drug Development Antiviral Drugs Advisory Committee Meeting November 2-3, 1999.

Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

TANZANIA AUGUST TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS.

CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.

HIV Post Exposure Prophylaxis

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

Community Participation in Research

Innovation: A Priority for FDA

Regulatory Issues in China

PhUSE Computational Science

Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”

ADVAC ALUMNI MEETING DURING SAGE

Every Mother, Every Child: Closing the Gaps in HIV Management

José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member

Presentation transcript:

Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training

Peter Karlton 2 The Imperative of Sexual Autonomy Any degree of efficacy is significant if it provides women with increased sexual autonomy, especially in circumstances where a woman has little or no control over the use of condoms.

Peter Karlton 3 Tenofovir 1% Gel Unique mechanism of action Absorbed into tissue and blood Prevents virus from growing Applied discretely 12 hours before and after coitus Low dose may reduce chance of resistance May slow progression of disease if women becomes infected

Peter Karlton 4 Creams and Gels: Unique Dosage Forms Require specialized training and expertise Unlike solid-oral dosage forms, e.g., Unique physical-chemical properties Specialized manufacturing and controls Compatibility with drug delivery applicators Complex stability characteristics

Peter Karlton 5 Opportunity for Collaboration: Academia, Regulatory, Industry Providing regulators with the tools to assess semi-solid dosage forms requires a commitment from both academia and the pharmaceutical industry.

Peter Karlton 6 Collaboration with Developing World Health Agencies Major regulatory agencies must work innovatively with developing world health agencies to create uniform guidance on the non-clinical and clinical development of TMs

Peter Karlton 7 FDA Guidance on Non-Clinical Development August 20, 2003, Antiviral Drugs Advisory Committee Meeting (Bethesda, MD) Clinical Development of Topical Microbicides: U.S. Regulatory Perspective, Teresa C. Wu, M.D., Ph.D., FDA, March 28-31, 2004, Microbicides 2004 Meeting, London, UK.

Peter Karlton 8 Additional Sources of Regulatory Significance Recommendations for the Development of Vaginal Microbicides, International Working Group on Vaginal Microbicides. AIDS May 4;15(7): Recommendations for the Development of Vaginal Microbicides Recommendations for the Nonclinical Development of Topical Microbicides for Prevention of HIV Transmission: An Update. J Acquire Immune Defic Syndr 2004, 36: Recommendations for the Nonclinical Development of Topical Microbicides for Prevention of HIV Transmission: An Update

Peter Karlton 9 Basic Assumptions About ART Registration in the Developing World Abbreviated dossier with summarized information. Known safety and efficacy of Viread and Truvada. Wide use in treatment centers. Physicians made repeated requests. “Not for profit” price structure. FDA approval would have influence.

Peter Karlton 10 Impediments to Rapid Review of Registration Dossiers Long delays in review and response time. Iterative and lengthy Q&A process. Requests for detailed CMC information. The unwillingness to accept approval by FDA or pre-qualification by WHO.

Peter Karlton 11 Thank you Contact for Peter Karlton: